Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. Triferic, available for use in the U.S., is the company’s leading FDA-approved iron maintenance therapy to keep dialysis patient’s hemoglobin in balance.
As an established manufacturer and leader in delivering high-quality, innovative drug therapies and hemodialysis concentrates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products used to save and sustain human life, removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Our life-sustaining products are not considered discretional in nature nor their use capable of being deferred.
The Company continues to develop unique, proprietary drug therapies for the treatment of iron-deficiency anemia for use in the renal, cancer, and pediatric medical areas These exclusive drug therapies support disease management initiatives to improve the quality of life and care of the patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience and outcome.
Triferic, is the only FDA-approved iron drug indicated to replace iron at every dialysis treatment and maintain hemoglobin in adult CKD-HD patient population in the United States. Triferic iron maintenance therapy delivers bio-available iron directly to the bone marrow to make hemoglobin for the treatment or prevention of iron deficiency anemia in dialysis patients.
Unlike current IV iron treatment administered by a nurse to treat anemia, Triferic is infused directly into the patient’s bloodstream during the dialysis treatment and transfers its iron load directly to transferrin at a cellular level, similar to normal dietary iron uptake. In January 2015, Rockwell received U.S. Food & Drug Administration (FDA) approval of Triferic as an iron replacement product to treat anemia and maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease. The Company has received patent protection in several countries including in the four largest ESRD markets in the world: the U.S., Japan, Europe and China.